Live-birth Rates After HP-hMG Stimulation in the Long GnRH Agonist Protocol: Association with Mid-follicular HCG and Progesterone Concentrations, but Not with LH Concentrations

Overview

Journal Gynecol Endocrinol

Publisher Informa Healthcare

Specialties Endocrinology
Gynecology & Obstetrics

Date 2012 Jul 20

PMID 22809021

Citations 2

Authors

Joan-Carles Arce

Johan Smitz

Affiliations

Soon will be listed here.

Abstract

The aim of this retrospective study was to investigate the impact of endogenous and exogenous luteinizing hormone (LH) activity on treatment outcome, when taking into consideration potential confounding variables. Data were derived from IVF patients (n = 358) stimulated with highly purified menotrophin (HP-hMG) in a long gonadotrophin-releasing hormone (GnRH) agonist protocol. Simple retrospective logistic regression analysis showed that the mid-follicular exogenous concentrations of human chorionic gonadotrophin (hCG) (p = 0.027), provided by the HP-hMG preparation, and female age (p = 0.009) were significantly associated with live-birth rate, while the mid-follicular progesterone concentration (p = 0.075), the estradiol concentration on last stimulation day (p = 0.075) and number of embryos transferred (p = 0.071) were borderline significant. Endogenous LH was not associated with live-birth rate; neither at start of stimulation (p = 0.123), nor in the mid-follicular phase (p = 0.933) or on the last day of stimulation (p = 0.589). In the multiple regression analysis of life birth, mid-follicular hCG (p = 0.016) was identified as a positive predictor, and age (p = 0.004) and mid-follicular progesterone (p = 0.029) as negative predictors. In conclusion, mid-follicular concentrations of exogenous hCG and progesterone, but not endogenous LH, are associated with live-birth rate in IVF patients treated with HP-hMG in a long GnRH agonist cycle.

Citing Articles

A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.

Sanchez M, Visnova H, Larsson P, Andersen C, Filicori M, Blockeel C Hum Reprod. 2022; 37(6):1161-1174.

PMID: 35451013 PMC: 9156848. DOI: 10.1093/humrep/deac061.

The effect of human chorionic gonadotrophin contained in human menopausal gonadotropin on the clinical outcomes during progestin-primed ovarian stimulation.

Zhu X, Ye J, Fu Y, Ai A, Cai R, Wang Y Oncotarget. 2017; 8(50):87340-87352.

PMID: 29152085 PMC: 5675637. DOI: 10.18632/oncotarget.20508.

References

Labarta E, Martinez-Conejero J, Alama P, Horcajadas J, Pellicer A, Simon C . Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011; 26(7):1813-25. DOI: 10.1093/humrep/der126. View

Van Vaerenbergh I, Fatemi H, Blockeel C, Van Lommel L, Int Veld P, Schuit F . Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online. 2011; 22(3):263-71. DOI: 10.1016/j.rbmo.2010.11.002. View

Propst A, Hill M, Bates G, Palumbo M, Van Horne A, Retzloff M . Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertil Steril. 2011; 96(4):898-904. DOI: 10.1016/j.fertnstert.2011.06.069. View

Filicori M, Cognigni G, Gamberini E, Parmegiani L, Troilo E, Roset B . Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005; 84(2):394-401. DOI: 10.1016/j.fertnstert.2005.02.036. View

Foster R, Segers I, Smart D, Adriaenssens T, Smitz J, Arce J . A differential cytokine expression profile is induced by highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone in a pre- and postovulatory mouse follicle culture model. Fertil Steril. 2009; 93(5):1464-76. DOI: 10.1016/j.fertnstert.2009.01.136. View

Smitz J, Andersen A, Devroey P, Arce J . Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2006; 22(3):676-87. DOI: 10.1093/humrep/del445. View

Arce J, Smitz J . Exogenous hCG activity, but not endogenous LH activity, is positively associated with live birth rates in anovulatory infertility. Hum Fertil (Camb). 2011; 14(3):192-9. PMC: 3251000. DOI: 10.3109/14647273.2011.587135. View

Kolibianakis E, Collins J, Tarlatzis B, Papanikolaou E, Devroey P . Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Hum Reprod Update. 2005; 12(1):3-12. DOI: 10.1093/humupd/dmi030. View

Coppola F, Poti E, Barusi L, Ferrari B, Salvarani M, Vadora E . Profound luteinizing hormone suppression induces a deleterious follicular environment during assisted reproduction technology. Fertil Steril. 2003; 79(2):459-60. DOI: 10.1016/s0015-0282(02)04671-x. View

10.

Fleming R, LLOYD F, Herbert M, Fenwick J, Griffiths T, Murdoch A . Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod. 1998; 13(7):1788-92. DOI: 10.1093/humrep/13.7.1788. View

11.

Fleming R, Jenkins J . The source and implications of progesterone rise during the follicular phase of assisted reproduction cycles. Reprod Biomed Online. 2010; 21(4):446-9. DOI: 10.1016/j.rbmo.2010.05.018. View

12.

Mansour R, Tawab N, Kamal O, El-Faissal Y, Serour A, Aboulghar M . Intrauterine injection of human chorionic gonadotropin before embryo transfer significantly improves the implantation and pregnancy rates in in vitro fertilization/intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril. 2011; 96(6):1370-1374.e1. DOI: 10.1016/j.fertnstert.2011.09.044. View

13.

Griesinger G, Dawson A, Schultze-Mosgau A, Finas D, Diedrich K, Felberbaum R . Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol. Fertil Steril. 2006; 85(3):791-3. DOI: 10.1016/j.fertnstert.2005.08.048. View

14.

Balasch J, Fabregues F, Casamitjana R, Penarrubia J, Vanrell J . A pharmacokinetic and endocrine comparison of recombinant follicle-stimulating hormone and human menopausal gonadotrophin in polycystic ovary syndrome. Reprod Biomed Online. 2003; 6(3):296-301. DOI: 10.1016/s1472-6483(10)61848-2. View

15.

Blockeel C, De Vos M, Verpoest W, Stoop D, Haentjens P, Devroey P . Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study. Hum Reprod. 2009; 24(11):2910-6. DOI: 10.1093/humrep/dep253. View

16.

Kosmas I, Zikopoulos K, Georgiou I, Paraskevaidis E, Blockeel C, Tournaye H . Low-dose HCG may improve pregnancy rates and lower OHSS in antagonist cycles: a meta-analysis. Reprod Biomed Online. 2009; 19(5):619-30. DOI: 10.1016/j.rbmo.2009.09.007. View

17.

Platteau P, Smitz J, Albano C, Sorensen P, Arce J, Devroey P . Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril. 2004; 81(5):1401-4. DOI: 10.1016/j.fertnstert.2003.09.077. View

18.

Serafini P, Yadid I, Motta E, Alegretti J, Fioravanti J, Coslovsky M . Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial. Fertil Steril. 2006; 86(4):830-8. DOI: 10.1016/j.fertnstert.2006.02.110. View

19.

Humaidan P, Bungum L, Bungum M, Andersen C . Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod. 2002; 17(8):2016-21. DOI: 10.1093/humrep/17.8.2016. View

20.

Ferrari B, Barusi L, Lanna M, Coppola F . Ovarian response and pregnancy outcome related to midfollicular LH levels in down-regulated women undergoing assisted reproduction. J Reprod Med. 2004; 49(3):148-52. View